Dalteparin Sodium

达肝素钠

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameDalteparin Sodium
Drug Alias Name达替肝素钠Tedelparin达特肝素钠BoxolTedelparine +[11] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionAntithrombin-III activatorsFactor Xa inactivationThrombin inactivation
TargetsAntithrombin-IIIProthrombinCoagulation factor X
Therapy Area/IndicationsCNS Embryonal TumorThrombophiliaAnemia, Sickle Cell +[27] 
Global Approved IndicationsThrombosisCoronary Artery Disease
Approved Indications in ChinaThrombosisCoronary Artery Disease
Original Approved Country/TerritoryGermany
Original Approved Date1985/01/01
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesSunnybrook Research InstitutePfizer Inc
Inactive CompaniesCanadian Institutes Of Health Research (Cihr)Johns Hopkins All Children'S Hospital IncUniversity Of Rochester +[9] 
Active IndicationsThrombosisVenous ThromboembolismMyocardial Infarction +[6] 
Inactive IndicationsCNS Embryonal TumorThrombophiliaAnemia, Sickle Cell +[21] 

Other Information

ATC CodeB01AB04
Related LinksWikipediaDrugBankKEGG